A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy

Journal of Clinical Oncology

Volumn 34, Issue 16, 2016, Pages 1913-1920

  McKay, Rana R ^a   Zurita, Amado J ^c   Werner, Lillian ^a   Bruce, Justine Y ^d   Carducci, Michael A ^e   Stein, Mark N ^g   Heath, Elisabeth I ^h   Hussain, Arif ^f   Tran, Hai T ^c   Sweeney, Christopher J ^a   Ross, Robert W ^b   Kantoff, Philip W ^a,i   Slovin, Susan F ⁱ   Taplin, Mary Ellen ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BLUEBIRD BIO   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^g RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^h KARMANOS CANCER INSTITUTE   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; VASCULOTROPIN A;

ADULT; ALLERGIC RHINITIS; ANDROGEN DEPRIVATION THERAPY; ARTHRITIS; ARTICLE; ASYMPTOMATIC DISEASE; BONE METASTASIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; FAINTNESS; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPONATREMIA; INFECTION; LOCAL THERAPY; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; MUSCULOSKELETAL PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; URINARY FREQUENCY; URINARY URGENCY; WEAKNESS; AGED; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

ADULT; AGED; ANDROGEN ANTAGONISTS; BEVACIZUMAB; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84973124554     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.3154     Document Type: Article

References (30)

1. Agarwal PK, Sadetsky N, Konety BR, et al: Treatment failure after primary and salvage therapy for prostate cancer: Likelihood, patterns of care, and outcomes. Cancer 112:307-314, 2008
2. Hussain M, Tangen CM, Berry DL, et al: Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-1325, 2013
3. Lin J, Kelly WK: Targeting angiogenesis as a promising modality for the treatment of prostate cancer. Urol Clin North Am 39:547-560, 2012
4. Bok RA, Halabi S, Fei DT, et al: Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A Cancer and Leukemia Group B study. Cancer Res 61: 2533-2536, 2001
5. Duque JL, Loughlin KR, Adam RM, et al: Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: Relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigen. Clinics (Sao Paulo) 61:401-408, 2006
6. George DJ, Halabi S, Shepard TF, et al: The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: Results from Cancer and Leukemia Group B 9480. Clin Cancer Res 11:1815-1820, 2005
7. Nicholson B, Gulding K, Conaway M, et al: Combination antiangiogenic and androgen deprivation therapy for prostate cancer: A promising therapeutic approach. Clin Cancer Res 10:8728-8734, 2004
8. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 370:2103-2111, 2007
9. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
10. Pujade-Lauraine E, Hilpert F, Weber B, et al: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 32:1302-1308, 2014
11. Reck M, von Pawel J, Zatloukal P, et al: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234, 2009
12. Saltz LB, Clarke S, Díaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 26:2013-2019, 2008
13. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006
14. Kelly WK, Halabi S, Carducci M, et al: Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534-1540, 2012
15. Scher HI, Halabi S, Tannock I, et al: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148-1159, 2008
16. Michaelson MD, Oudard S, Ou YC, et al: Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32:76-82, 2014
17. Petrylak DP, Vogelzang NJ, Budnik N, et al: Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 16:417-425, 2015
18. Smith MR, De Bono JS, Sternberg CN, et al: Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). J Clin Oncol 33, 2015 (suppl 7; abstr 139)
19. Tannock IF, Fizazi K, Ivanov S, et al: Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial. Lancet Oncol 14:760-768, 2013
20. Sweeney CJ, Chen YH, Carducci M, et al: Chemohormonal therapy in metastatic hormonesensitive prostate cancer. N Engl J Med 373: 737-746, 2015
21. Sweeney CJ, Miller KD, Sissons SE, et al: The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 61:3369-3372, 2001
22. McKay RR, Gray KP, Hayes JH, et al: Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer 121:2603-2611, 2015
23. Ross RW, Galsky MD, Febbo P, et al: Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial. Cancer 118:4777-4784, 2012
24. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 189:S34-S42, 2013 (suppl 1); discussion S43-S44
25. Smith MR, Finkelstein JS, McGovern FJ, et al: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603, 2002
26. Mistry T, Digby JE, Desai KM, et al: Obesity and prostate cancer: A role for adipokines. Eur Urol 52:46-53, 2007
27. Anborgh PH, Mutrie JC, Tuck AB, et al: Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal 5: 111-122, 2011
28. Castellano G, Malaponte G, Mazzarino MC, et al: Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 14:7470-7480, 2008
29. Nixon AB, Halabi S, Shterev I, et al: Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance). J Clin Oncol 31, 2013 (suppl; abstr 4520)
30. Tran HT, Liu Y, Zurita AJ, et al: Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13:827-837, 2012